An exciting pharma stock to consider alongside GlaxoSmithKline plc

GlaxoSmithKline plc (LON: GSK) would make a great pairing with this potential blockbuster growth firm.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I reckon GlaxoSmithKline (LSE: GSK) is a great stock to hold in a long-term portfolio because the pharmaceutical industry is known for its defensive characteristics, but read on for an idea that could complement the stock in your portfolio.

Recovering slowly

It’s well known that the pharmaceutical giant has been challenged in recent years by many of its best-selling treatments running out of time on their patent protection. The firm’s five-year record on earnings shows a steady decline and a bounce-back during 2016, but during the period the dividend held flat. Looking forward, City analysts following it predict 8% growth in earnings in 2017 and 3% during 2018. It looks like the firm’s operations are recovering, driven by ongoing R&D progress with a steady flow of new blood from the development pipeline.

Maybe GlaxoSmithKline will score big with a new patent-protected blockbuster in the future. In the meantime, steady cash inflow keeps the firm looking attractive. At today’s share price of 1,526p, you can pick up some of the shares on a forward price-to-earnings (P/E) ratio a little over 13 for 2018. And the forward dividend yield runs just above 5% with those forward earnings expected to cover the payout around 1.4 times.

This is a defensive, dividend-paying stalwart, but the pharmaceutical sector offers excitement too, and we can get some of it in our portfolios by moving further towards earlier-stage R&D-focused outfits that have yet to generate the gargantuan cash flows of a firm like GlaxoSmithKline. I think there’s a good case for pairing it with a firm such as Summit Therapeutics (LSE: SUMM), which released its interim results today.

Well-cashed

The drug discovery and development company is working on therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI). As with all early-stage drug development firms, the goal is to end up with a marketable product that can go on to generate revenue and profit, but such firms are known for burning cash and raising funds. However, Summit Therapeutics seems to have passed its most-precarious lossmaking stage.

During October 2016, the firm signed up to an exclusive licence and collaboration agreement with Sarepta Therapeutics Inc. Sarepta and Summit will collaborate to develop therapies for patients with DMD and share R&D costs. Summit received $40m up front from Sarepta, which helped stabilise the company’s financial position. The terms of the deal allow for potential future milestone payments to Summit of up to $522m.

A bridge to commercialisation

Summit also has an option to take up rights to the market in Latin America. Assuming that development goes well, it looks like it has a decent bridge to commercialisation in place and a route to market-generated revenues. Meanwhile, development progress is advanced. The firm expects to report results of a proof-of-concept trial for its potential DMD treatment, Ezutromoid in the first quarter of 2018 and to start phase 3 clinical trials with its C. difficile treatment Ridinilazole during the first half of 2018.

I think Summit Therapeutics looks well-placed and is worthy of your research right now. If things continue to go well for the firm, we could end up seeing multiples of the current 185p share price, but if the trials fail, the shares could move a long way in the wrong direction.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold does not own any shares in Summit Theraputics or in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »